The Brno-based outfit has developed FGF2-STAB, a stabilized growth factor that offers a novel way to grow fibroblast growth factor-2 dependent cell cultures more efficiently, with fewer media changes.
Enantis will receive a $10,000 grant, access to the Estée Lauder New Incubation Ventures (NIV) mentorship programme, as well as use of the NIV Network.
“This remarkable recognition propels us forward, empowering us to forge vital connections within the cosmetics industry and propel our groundbreaking FGF2-STAB product into the market,” the company said.
“This win comes as an unexpected yet immensely welcome validation of our efforts, especially considering we have just launched our first cosmetics product,” it added.
Enantis beat off four finalists: Ascension Medical Biotechnology from Taiwan, Ireland’s Oriel Marine Extracts, Paris-based Sethic Innovations and SupadElixir of South Korea.
